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Improved understanding of the molecular mechanisms
of secondary brain injury has informed the optimum
depth and duration of cooling and led to increased
clinical interest in the therapeutic moderate hypothermia
for severe traumatic brain injury over the past two
decades. Although several large multi-center clinical trials
have not found a treatment effect, multiple single-center
trials have, and a recent meta-analysis by Crossley and
colleagues now finds that the cumulative findings of
those single-center trials dilute the multi-center trial
results and show an overall reduction in mortality and
poor outcomes associated with cooling. The need for
consistent support of key physiologic parameters during
cooling is emphasized by this finding.2001) that did not find any benefit with the treatment
compared with a normothermia control group. SubsequentIntroduction
A recent meta-analysis of clinical trials of the use of
hypothermia to treat severe traumatic brain injury (TBI) is
the first report in nearly 15 years to suggest improved out-
comes associated with cooling [1]. Therapeutic moderate
hypothermia (32 to 35°C) for the acute care of patients with
severe TBI has been evaluated in multiple clinical trials dur-
ing the past 20 years, especially in the US, Japan, and China.
A review of 11 prospective randomized clinical trials
that compared intracranial pressure (ICP) levels with
hypothermia versus normothermia treatment and six pro-
spective cohort studies that provided ICP data before and
during hypothermia treatment found that therapeutic mod-
erate hypothermia was surpassed only by hypertonic saline,
lumbar cerebrospinal fluid drainage, and decompressive
craniectomy in the level of ICP reduction [2]. There are
several mechanisms through which cooling may reduce* Correspondence: donald.w.marion.ctr@mail.mil
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2014swelling following an injury, including a reduction of pro-
inflammatory cytokine levels, decreasing the cellular in-
flammatory response, and stabilization of the blood–brain
barrier. Pre-clinical brain injury studies have consistently
found reduced lesion volume, reduced inflammation, and
improved functional outcomes with post-injury cooling.
Beneficial effects on these mechanisms are consistent with
the apparent efficacy of hypothermia for neonatal hypoxic-
ischemic encephalopathy and pre-hospital cardiac arrest.
Indeed, therapeutic moderate hypothermia is now recog-
nized as the clinical standard of care for these two diseases.
Prospective multicenter trials have not found benefit
Enthusiasm for the treatment of patients with severe TBI
with moderate hypothermia was significantly dampened by
a large prospective randomized clinical trial (published in
Cochrane meta-analyses of all clinical trials of hypothermia
for TBI also could not discern an overall benefit. In fact, a
pediatric multi-center trial actually suggested an increased
mortality rate in the hypothermia group compared with
the control group.
The findings of the meta-analysis by Crossley and col-
leagues [1] are therefore surprising and unexpected. The
study appears to be methodologically sound: they appro-
priately tested the level of bias and heterogeneity among
studies they included in the analysis, and they provided
a separate analysis of data from studies with a low risk
of bias. Both the cumulative and ‘low risk of bias’ data
sets showed significant positive effects of hypothermia.
The authors used relative risk (RR) as their measure of
the analysis. Outcome events (death and poor outcomes
such as long-term disability) in the TBI population are
not rare events and, under such a scenario, RR tends to
be biased and odds ratios are preferred by some. How-
ever, since the authors are not actually comparing the
odds of developing an outcome (death) among groups
(gender, age group, and so on) with respect to theirentral Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Marion and Regasa Critical Care Page 2 of 22014, 18:160
http://ccforum.com/content/18/3/160exposure (hypothermia), the simplest and easiest meas-
ure (RR) is acceptable.
There is an apparent distinction between single-center
versus multi-center trials, however, and this has been
observed by others [3]. In the report by Crossley and
colleagues, 17 studies described mortality rates in the
hypothermia and normothermia groups that included at
least 10 patients in each group. The three multi-center
studies - Clifton and colleagues (2001 [4] and 2011 [5]) and
Maekawa (2009) [6] - found either no difference or worse
mortality rates in the hypothermia groups, but all of the 14
single-center studies found that therapeutic hypothermia
was associated a lower mortality rate. Likewise, for clinical
studies with 10 or more subjects in the treatment and con-
trol groups, there were significantly fewer poor outcomes
in the hypothermia groups, but only in the single-center
studies and not in the multi-center studies. A significant
variation in critical care across sites was reported for the
NABIS: H (National Brain Injury Study: Hypothermia)
multi-center study and could confound hypothermic treat-
ment effects [4]. For example, frequent occurrences of
hypotension or hypovolemia in some of the centers of the
multi-center trial could result in an increased incidence of
poor treatment-related outcomes that could dilute the good
treatment-related outcomes seen in the other centers. One
could argue that the experimental treatment cannot be very
robust if it cannot be shown to be beneficial in a multi-
center trial which more closely resembles the real world.
Two large pediatric multi-center clinical trials were ex-
cluded from this analysis, but there is no clear evidence that
the hypothermia effect should be substantially different for
children than it is for adults. If the pediatric studies by
Adelson and colleagues [7] and Hutchison and colleagues
[8] had been included, the meta-analysis may not have
found a benefit, particularly with the latter study finding a
significant increase in mortality in the hypothermia group.
Clinical trials of therapeutic moderate hypothermia for
severe TBI are still ongoing. The Eurotherm 3235 Trial is
an international, multi-center, randomized controlled trial
which is examining the effects of titrated therapeutic
hypothermia (32 to 35°C) and is coordinated by Peter
Andrews at Western General Hospital, Edinburgh, and has
enrolled more than 300 of the targeted 600 patients. Clifton
(personal communication) has organized a new random-
ized clinical trial to look just at those patients with surgical
intracranial mass lesions. Maekawa [9] completed a multi-
center study of 150 subjects in 2008 and has presented pre-
liminary data at several meetings.
Conclusions
In addition to endorsing focused treatment based on the
type of cranial injury, most believe it is important to cool
the patient to target temperature as quickly as possible,
preferably within 4 to 6 hours after the injury. Intravascularcooling technology to allow such rapid cooling and to bet-
ter maintain the patient at target temperature currently ex-
ists. With more rapid cooling and better selection of the
candidates for this therapy, it is possible if not likely that
future multi-center trials will find the therapeutic efficacy
that single-center studies already have found. However, it
is clear that there will need to be close monitoring of
the acute care of these patients to ensure consistency of
support of blood pressure, intravascular volume, and other
aspects of medical management across the centers.
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